Barclays PLC Roivant Sciences Ltd. Transaction History

Barclays PLC

$327 Billion
Q2 2024

A detailed history of Barclays PLC transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Barclays PLC holds 383,912 shares of ROIV stock, worth $4.48 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

383,912

Previous 446,962 14.11%

Holding current value

$4.48 Million

Previous $4.71 Million 13.86%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$10.36 - $11.74 $653,198 - $740,207	-63,050 Reduced 14.11%	383,912 $4.06 Million
Q1 2024 May 15, 2024	BUY	$9.87 - $11.8 $519,083 - $620,585	52,592 Added 13.34%	446,962 $4.71 Million
Q4 2023 Feb 15, 2024	BUY	$8.38 - $11.58 $203,801 - $281,625	24,320 Added 6.57%	394,370 $4.43 Million
Q3 2023 Nov 07, 2023	SELL	$9.76 - $13.19 $196,966 - $266,187	-20,181 Reduced 5.17%	370,050 $4.32 Million
Q2 2023 Aug 03, 2023	BUY	$7.09 - $10.08 $1.12 Million - $1.6 Million	158,363 Added 68.3%	390,231 $3.93 Million
Q1 2023 May 04, 2023	BUY	$6.92 - $9.98 $722,669 - $1.04 Million	104,432 Added 81.95%	231,868 $1.71 Million
Q4 2022 Feb 13, 2023	BUY	$3.36 - $7.99 $417,701 - $993,284	124,316 Added 3984.49%	127,436 $1.02 Million
Q3 2022 Nov 03, 2022	SELL	$0.51 - $4.84 $7,647 - $72,575	-14,995 Reduced 82.78%	3,120 $10,000
Q2 2022 Aug 12, 2022	BUY	$2.81 - $4.84 $21,173 - $36,469	7,535 Added 71.22%	18,115 $74,000
Q1 2022 May 16, 2022	BUY	$4.74 - $9.91 $50,149 - $104,847	10,580 New	10,580 $52,000

Others Institutions Holding ROIV

# of Institutions

314

Shares Held

496M

Call Options Held

991K

Put Options Held

1.15M

View Full List

About Roivant Sciences Ltd.

Ticker ROIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 704,382,976
Market Cap $8.23B
Description
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...

More about ROIV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account